Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]

Draft guidance

Draft guidance (online commenting)

Draft guidance (downloadable version) (PDF 310 KB)

Committee papers - ACM1 (PDF 9.33 MB)

Public committee slides - ACM1 (PDF 775 KB)

Final scope (PDF 199 KB)

Final stakeholder list (PDF 155 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 228 KB)

Note

Draft scope post referral (PDF 254 KB)